The acquisition increases Aceto’s GMP manufacturing, packaging and ingredients offerings for the cell culture, vaccine and biopharma industries, as well as expanding its North American footprint.

“With the acquisition of A&C, Aceto has materially expanded its self-manufactured and custom product offerings in the vaccine and biopharmaceutical space,” said Gilles Cottier, Aceto’s CEO.

Aceto said it will continue to support A&C’s manufacturing facilities and offices in the US, Canada, and Ireland.

The deal is the third Aceto has done in the past 12 months. Last December, it took over IsleChem, a company focused on chemical manufacturing, contract research and development, analytical services, and technical and support services for the pharmaceutical, agricultural, medical, automotive and electronics industries.

In April 2020, Aceto added Syntor Fine Chemicals to its stable. UK-based Syntor manufactures fine chemicals for the pharma and other life sciences markets.

Aceto filed a voluntary petition under Chapter 11 of the US Bankruptcy Code in February 2019, as it began the process of selling its chemicals and pharmaceuticals units in separate transactions.

New Mountain Capital purchased Aceto’s chemicals business for $338 million in April 2019, when Shore Suven Pharma – a joint venture between India’s Suven Life Sciences and US-based Shore Pharma Investments – bought the pharma business, called Rising Pharmaceuticals.

Author: Elaine Burridge, Freelance Journalist